Back to search results

SELECT LATE Trial: Endovascular Thrombectomy for Acute Ischemic Stroke Beyond 24 Hours

This study, called SELECT LATE, is looking at whether adding Endovascular Thrombectomy (a procedure to remove blood clots from brain arteries) to standard medical care helps people who have had a severe stroke. This is for patients who come to the hospital between 24 and 72 hours after their stroke symptoms started. Researchers want to see if this combination leads to better recovery and functional outcomes, measured by the modified Rankin Scale (a scale that assesses disability) 90 days after the stroke. You might be able to join if you are an adult between 18 and 85 years old, have had a recent severe ischemic stroke, and meet other specific medical criteria. The study aims to enroll 408 participants.

Study design
This is a randomized, international, multicenter study where participants will be assigned by chance to either receive Endovascular Thrombectomy plus medical management, or medical management alone. Researchers will not know which treatment you receive. The study plans to enroll 408 participants.
What's involved
You will have assessments at the start of the study, 24 hours after randomization, at discharge, 90 days, and 1 year. The specific procedures for these assessments are not detailed.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 1 year after treatment, with a primary assessment at 90 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07115940

Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well

Recruiting
NAAges 18–85InterventionalTreatment
Amrou Sarraj
~408 participants
Updated 2026-07-06 on ClinicalTrials.gov
What's tested:Endovascular ThrombectomyMedical Management

At a glance

Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The distribution of the modified Rankin Scale score
Measured over 90 days ± 15 days

Conditions

Acute Ischemic Stroke

Explore related trials

Acute Ischemic Stroke

NCT07115940

Where you'd take part

This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Baylor University Medical Center

    Dallas, Texasstudy coordinator listed

    Recruiting

  • Rhode Island Hospital

    Providence, Rhode Islandstudy coordinator listed

    Recruiting

  • The University of Kansas Health System

    Kansas City, Kansasstudy coordinator listed

    Recruiting

  • University of Chicago

    Chicago, Illinoisstudy coordinator listed

    Recruiting

  • Washington University School of Medicine

    St Louis, Missouristudy coordinator listed

    Recruiting

  • West Virginia University

    Morgantown, West Virginiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Amrou Sarraj, MD · PRINCIPAL_INVESTIGATOR · University Hospitals

Who to contact

Kate Rownd, MED
[email protected]
216-286-6458
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults (18-85\* years) with the final diagnosis of an acute ischemic stroke$
NIHSS ≥ 6
Time from last-known-well to randomization \>24 - 72 hours
Pre-stroke modified Rankin Scale score of 0-1
Eligible for thrombectomy and medical management
Signed Informed Consent obtained
Subject willing to comply with the protocol follow-up requirements
Anticipated life expectancy of at least 3 months \*Inclusive of both 18 and 85 years of age (i.e. up to 86th birthdate). $Subacute presentation - In-hospital stroke admissions with fluctuating clinical symptoms for patients who presented to EVT centers within 24 hours of when they were last known well will not be eligible for the trial.
Proven large vessel occlusion in ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions), as determined by MR Angiography (MRA) or CT Angiography (CTA)
CT ASPECTS 3-10
CT Perfusion ischemic core (rCBF \<30%)# volume ≤150 ml OR MR Diffusion ischemic core (ADC \<620x10-6 mm2/s)# volume ≤150ml #If the perfusion software at enrollment center uses another threshold/measure to define ischemic core, please use that measure to assess ischemic core criteria.

Exclusion

Current participation in another investigational interventional drug or device study.
Baseline Platelet count \<100,000/μl
Evidence of intracranial tumor (except small meningioma \<3cm without signs of edema or inflammation), acute intracranial hemorrhage, or arteriovenous malformation
Significant mass effect, defined as midline shift (\>3mm) using foramen of monroe (anterior margin of third ventricle) as the marker for midline instead of septum pellucidum AND/OR Effacement of sulci in contralateral hemisphere
Evidence of internal carotid artery dissection that is flow limiting or aortic dissection
Intracranial stent implanted in the same vascular territory that precludes the safe deployment/removal of the neurothrombectomy device
Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion).
Any signs of established infarct, demarcating hypodensity and area of cerebral edema on non-contrast CT
CT ASPECTS 0-2
CT Perfusion ischemic core (rCBF \<30%)# volume \>150 ml OR MR Diffusion ischemic core (ADC \<620x10-6 mm2/s)# volume \>150ml #If the perfusion software at enrollment center uses another threshold/measure to define ischemic core, please use that measure to assess ischemic core criteria.

What this trial measures

  • The distribution of the modified Rankin Scale score90 days ± 15 days

    The modified Rankin Scale (a 7-point scoring system, 0 indicates no residual stroke symptoms and 6 represents death) is assessed through patient/caregiver interview by trained and certified raters. The modified Rankin Scale score is the standard FDA-recognized measure of stroke outcome, used in clinical trials testing acute stroke therapies.